# Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma

> **NCT04480099** · PHASE2 · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 96 (actual)

## Conditions studied

- Peripheral T-cell Lymphoma

## Interventions

- **DRUG:** CHOP
- **DRUG:** CHOP+X

## Key facts

- **NCT ID:** NCT04480099
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-29
- **Primary completion:** 2023-04-20
- **Final completion:** 2024-04
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2023-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04480099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04480099, "Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04480099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*